EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evolving landscape of targeted therapies in early phase clinical trials

Alice Rossi, Irene Braña, Maria Vieito, Oriol Mirallas, Victor Navarro, Omar Saavedra, Guzman Alonso Casal, Vladimir Galvao, M Julia Lostes Bardaji, Arjun Oberoi, Giulia Pretelli, Marta Sanz und 22 weitere

European Journal of Cancer · 2026-06 · 240 · 116745

DOI: 10.1016/j.ejca.2026.116745 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Alice Rossi und 33 weiteren Autor:innen. Beteiligte Einrichtung: Vall d´Hebron Institute of Oncology, Barcelona, Spain. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Foundation, Instituto de Salud Carlos III, Fundación la Caixa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Targeted TherapyNeoplasmsAntineoplastic AgentsHumansClinical Trials as TopicProspective StudiesFemaleProgression-Free SurvivalMaleMiddle AgedAged

Stichwörter der Autor:innen

Early phase clinical trialsMolecular prescreeningPrecision oncologyTargeted therapies

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Vall d´Hebron Institute of Oncology, Barcelona, Spain.
  • Vall d´Hebron Institute of Oncology, Barcelona, Spain; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, IIS IR-HUVH, Barcelona, Spain.
  • Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, IIS IR-HUVH, Barcelona, Spain.
  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vall d´Hebron Institute of Oncology, Barcelona, Spain; University of Vic - Central University of Catalonia, Vic, Spain.
  • Vall d´Hebron Institute of Oncology, Barcelona, Spain; Department of Medical Oncology, Vall d'Hebron Barcelona Hospital Campus, IIS IR-HUVH, Barcelona, Spain. Electronic address: albertohernando@vhio.net.

Förderung

  • Gilead Foundation
  • Instituto de Salud Carlos III
  • Fundación la Caixa

Zitieren

APA

Rossi, A., Braña, I., Vieito, M., Mirallas, O., Navarro, V., Saavedra, O., Casal, G. A., Galvao, V., Bardaji, M. J. L., Oberoi, A., Pretelli, G., Sanz, M., Bueno, S. A., Abril, B. F., Izquierdo, S. A., Jimenez, J., Nuciforo, P., Vivancos, A., Oliveira, M., …, & Hernando-Calvo, A. (2026). Evolving landscape of targeted therapies in early phase clinical trials. European Journal of Cancer, 240, 116745. https://doi.org/10.1016/j.ejca.2026.116745

Vancouver

Rossi A, Braña I, Vieito M, Mirallas O, Navarro V, Saavedra O, et al. Evolving landscape of targeted therapies in early phase clinical trials. European Journal of Cancer. 2026;240:116745. doi:10.1016/j.ejca.2026.116745

BibTeX
@article{Rossi2026,
  author = {Rossi, Alice and Braña, Irene and Vieito, Maria and Mirallas, Oriol and Navarro, Victor and Saavedra, Omar and Casal, Guzman Alonso and Galvao, Vladimir and Bardaji, M Julia Lostes and Oberoi, Arjun and Pretelli, Giulia and Sanz, Marta and Bueno, Sergio Andres and Abril, Benet Fite and Izquierdo, Susana Aguilar and Jimenez, Jose and Nuciforo, Paolo and Vivancos, Ana and Oliveira, Mafalda and Baraibar, Iosune and Castet, Florian and Duran, Carmen Garcia and Ahnert, Jordi Rodon and Capdevila, Jaume and Galceran, Joan Carles and Macarulla, Teresa and Saura, Cristina and Felip, Enriqueta and Elez, Elena and Tabernero, Josep and Dienstmann, Rodrigo and Villacampa, Guillermo and Garralda, Elena and Hernando-Calvo, Alberto},
  title = {Evolving landscape of targeted therapies in early phase clinical trials},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {240},
  pages = {116745},
  doi = {10.1016/j.ejca.2026.116745}
}
Kostenlos starten →